ライフサイエンスコーパス: diffuse large B-cell lymphoma

1 op an aggressive malignancy resembling human diffuse large B cell lymphoma.

2 opathy, Waldenstrom's macroglobulinemia, and diffuse large B cell lymphoma.

3 ecially for those with aggressive forms like diffuse large B-cell lymphoma.

4 able to transform into germinal center-type diffuse large B-cell lymphoma.

5 efiting patients with follicular lymphoma or diffuse large B-cell lymphoma.

6 tality for anal cancer, Hodgkin lymphoma, or diffuse large B-cell lymphoma.

7 development of FL and its transformation to diffuse large B-cell lymphoma.

8 Genetic markers have helped to prognosticate diffuse large B-cell lymphoma.

9 oblastic leukemia, plasma cell neoplasms, or diffuse large B-cell lymphoma.

10 (EFS24) is a clinically useful end point in diffuse large B-cell lymphoma.

11 notherapy in untreated elderly patients with diffuse large B-cell lymphoma.

12 issues when treating patients with high-risk diffuse large B-cell lymphoma.

13 a quarter of Burkitt lymphoma and GC-derived diffuse large B-cell lymphoma.

14 prove the outcome of high-risk patients with diffuse large B-cell lymphomas.

15 cated for the routine staging of HL and most diffuse large B-cell lymphomas.

16 st common mature noncutaneous lymphomas were diffuse large B-cell lymphomas (32.4%), follicular lymph

17 remission occurred in 6 of 14 patients with diffuse large B-cell lymphoma (43%; 95% CI, 18 to 71) an

18 ese, 12 (21%) had Hodgkin lymphoma, 22 (39%) diffuse large B-cell lymphoma, 5 (9%) Burkitt lymphoma,

19 For diffuse large B-cell lymphoma, 5-year net survival in no

20 Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin

21 ctory cancers, such as activated B cell-like diffuse large B cell lymphoma (ABC DLBCL), are likely re

22 ted in the activated B-cell-like subgroup of diffuse large B-cell lymphoma (ABC DLBCL) to drive aberr

23 scriptional network of activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL), an aggressive

24 Three patients with diffuse large B-cell lymphoma achieved durable objective

25 Additionally, BCL-W was overexpressed in diffuse large B cell lymphoma and correlated with decrea

26 rmed B cells in vitro; however, EBV-positive diffuse large B cell lymphomas and Burkitt lymphomas oft

27 iling in 177 cancer cell lines revealed that diffuse large B cell lymphomas and renal cell carcinomas

28 cytic leukemia, 29% of activated B-cell type diffuse large B-cell lymphoma and 90% of Waldenstrom mac

29 uently in follicular lymphoma and aggressive diffuse large B-cell lymphoma and are associated with H3

30 e in the treatment of relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.

31 requently mutated in germinal center-derived diffuse large B-cell lymphoma and follicular lymphoma.

32 perior to the 5-point scale in patients with diffuse large B-cell lymphoma and may also improve the a

33 Diffuse large B-cell lymphoma and MCL had a poor prognos

34 h FOXP1 expression is frequently observed in diffuse large B-cell lymphoma and mucosa-associated lymp

35 consolidation radiotherapy in patients with diffuse large B-cell lymphoma and primary mediastinal B-

36 nrolled patients with relapsed or refractory diffuse large B-cell lymphoma and relapsed or refractory

37 One patient developed diffuse large B-cell lymphoma and subsequently leukemia,

38 lymphomas had some of the characteristics of diffuse large B-cell lymphomas and contained monoclonal,

39 ld be detected in the serum of patients with diffuse large-B-cell lymphoma and used to predict clinic

40 , an enhanced expression was observed in HL, diffuse large B-cell lymphoma, and lymphoblastoid cell l

41 acetylation signature in the ABC subgroup of diffuse large B-cell lymphoma, and one of the most frequ

42 ent, and viral components in 41 AIDS-related diffuse large B-cell lymphomas (AR-DLBCLs) in the pre- a

43 nversely, the D2HGDH mutants that we find in diffuse large B-cell lymphoma are enzymatically inert.

44 Diffuse large B-cell lymphoma arising in immune-privileg

45 ic active B-cell receptor (BCR) signaling in diffuse large B-cell lymphoma as a model system to estab

46 Remarkably, diffuse large B cell lymphoma-associated gain-of-functio

47 In germinal center diffuse large B-cell lymphoma, BCL-2 levels or venetocla

48 chemotherapy in older patients with advanced diffuse large B-cell lymphoma, but further comparative s

49 chemotherapy in older patients with advanced diffuse large B-cell lymphoma, but further comparative s

50 he vast majority of cases are histologically diffuse large B-cell lymphoma, but rarer subtypes are cl

51 We considered follicular lymphoma and diffuse large B-cell lymphoma cases in patients aged old

52 tified 13,988 follicular lymphoma and 25,320 diffuse large B-cell lymphoma cases.

53 PI3K-dependent Erk phosphorylation in human diffuse large B-cell lymphoma cell lines.

54 re, RNF181 limits the proliferation of human diffuse large B cell lymphoma cells that depend upon abe

55 rts direct cytotoxicity on IL-21R-expressing diffuse large B-cell lymphoma cells.

56 utcomes in patients older than 60 years with diffuse large B-cell lymphoma compared with CHOP every 3

57 Primary lymphoma of the CNS (PCNSL) is a diffuse large B cell lymphoma confined to the CNS.

58 nts represent promising treatment targets in diffuse large B cell lymphoma (DLBCL) and additional B c

59 rent and occur early during tumorigenesis in diffuse large B cell lymphoma (DLBCL) and follicular lym

60 tutively activate CARMA1 occur frequently in diffuse large B cell lymphoma (DLBCL) and mediate essent

61 on mutations that are frequently observed in diffuse large B cell lymphoma (DLBCL) and that disrupt I

62 ogenic BCL6 and EZH2 cooperate to accelerate diffuse large B cell lymphoma (DLBCL) development and co

63 of CD37 on neoplastic cells in patients with diffuse large B cell lymphoma (DLBCL) directly correlate

64 Diffuse large B cell lymphoma (DLBCL) is a biologically

65 Diffuse large B cell lymphoma (DLBCL) is the most common

66 Diffuse large B cell lymphoma (DLBCL) is the most common

67 oyment of rationally developed therapies for diffuse large B cell lymphoma (DLBCL) requires rapid ass

68 f the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), engages the CARD1

69 n the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), the oncogenic MYD

70 The two major subtypes of diffuse large B cell lymphoma (DLBCL)--activated B cell-

71 ly overlaps with that in the closely related diffuse large B cell lymphoma (DLBCL).

72 ansplant recipients have heightened risk for diffuse large B cell lymphoma (DLBCL).

73 ening to identify novel tumor suppressors in diffuse large B cell lymphoma (DLBCL).

74 germinal center (GC) B cell-like subtypes of diffuse large B cell lymphoma (DLBCL).

75 port integrative genetic characterization of diffuse large B cell lymphomas (DLBCL), including large-

76 expression of these miRNAs also occurred in diffuse large B cell lymphomas (DLBCL), which are strong

77 ]), follicular lymphoma (FL) (23% [n = 20]), diffuse large B-cell lymphoma (DLBCL) (10% [n = 9]), man

78 cell lymphoma (MCL) (6.8% [18 of 263]), and diffuse large B-cell lymphoma (DLBCL) (4.6% [12 of 263).

79 arge B-cell lymphoma (PMBCL) is a subtype of diffuse large B-cell lymphoma (DLBCL) accounting for 2%

80 Diffuse large B-cell lymphoma (DLBCL) accounts for 30% t

81 Few patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) achieve prolonged

82 The PI3K-mTORC pathway is upregulated in diffuse large B-cell lymphoma (DLBCL) and can be targete

83 ing of the pathogenesis and heterogeneity of diffuse large B-cell lymphoma (DLBCL) and follicular lym

84 The standardized incidence ratios (SIRs) of diffuse large B-cell lymphoma (DLBCL) and follicular lym

85 antibody, was superior to rituximab in human diffuse large B-cell lymphoma (DLBCL) and mantle-cell ly

86 oncogene in activated B-cell-like subtype of diffuse large B-cell lymphoma (DLBCL) and mucosa-associa

87 Here, we interrogate the MNK-eIF4E axis in diffuse large B-cell lymphoma (DLBCL) and show a distinc

88 promotes degradation of Aiolos and Ikaros in diffuse large B-cell lymphoma (DLBCL) and T cells in vit

89 Studies of diffuse large B-cell lymphoma (DLBCL) are typically eval

90 e-expressor lymphomas (DELs) are subtypes of diffuse large B-cell lymphoma (DLBCL) associated with po

91 Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with

92 shRNA knockdown showed that almost all diffuse large B-cell lymphoma (DLBCL) cell lines are add

93 ably, inhibition of the miR-17~92 cluster in diffuse large B-cell lymphoma (DLBCL) cell lines diminis

94 we used the miR-155 knockout (KO) mouse and diffuse large B-cell lymphoma (DLBCL) cell lines ectopic

95 e Lymph2Cx digital gene expression assay for diffuse large B-cell lymphoma (DLBCL) cell-of-origin det

96 nce that GLI1 contributes to the survival of diffuse large B-cell lymphoma (DLBCL) cells and that thi

97 scription factor (ATF) family in survival of diffuse large B-cell lymphoma (DLBCL) cells.

98 me data from a large cohort of patients with diffuse large B-cell lymphoma (DLBCL) compared with norm

99 f transplant-eligible patients with relapsed diffuse large B-cell lymphoma (DLBCL) consists of rituxi

100 nical features from 1650 adults with de novo diffuse large B-cell lymphoma (DLBCL) diagnosed from 200

101 ospectively enrolled cohort of patients with diffuse large B-cell lymphoma (DLBCL) from the United St

102 Distinct subgroups of diffuse large B-cell lymphoma (DLBCL) genetically resemb

103 Up to 40% of elderly patients with untreated diffuse large B-cell lymphoma (DLBCL) given a regimen of

104 Diffuse large B-cell lymphoma (DLBCL) has been categoriz

105 ostic significance of MDM2 overexpression in diffuse large B-cell lymphoma (DLBCL) has not been defin

106 er latency to the development of BCL6-driven diffuse large B-cell lymphoma (DLBCL) in a murine model.

107 Routine imaging for diffuse large B-cell lymphoma (DLBCL) in first complete

108 llance imaging of asymptomatic patients with diffuse large B-cell lymphoma (DLBCL) in first remission

109 urpose The general outlook for patients with diffuse large B-cell lymphoma (DLBCL) in first remission

110 Diffuse large B-cell lymphoma (DLBCL) is a genetically h

111 Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous

112 Diffuse large B-cell lymphoma (DLBCL) is an aggressive d

113 Diffuse large B-cell lymphoma (DLBCL) is an aggressive d

114 Diffuse large B-cell lymphoma (DLBCL) is an aggressive d

115 Germinal center (GC)-derived diffuse large B-cell lymphoma (DLBCL) is known to be dri

116 Effective treatment of diffuse large B-cell lymphoma (DLBCL) is plagued by hete

117 pose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in co

118 Diffuse large B-cell lymphoma (DLBCL) is stratified into

119 Diffuse large B-cell lymphoma (DLBCL) is the most common

120 Diffuse large B-cell lymphoma (DLBCL) is the most common

121 Diffuse large B-cell lymphoma (DLBCL) is the most common

122 Diffuse large B-cell lymphoma (DLBCL) is the most common

123 Diffuse large B-cell lymphoma (DLBCL) is the most common

124 Diffuse large B-cell lymphoma (DLBCL) is the most common

125 Diffuse large B-cell lymphoma (DLBCL) is the most common

126 Diffuse large B-cell lymphoma (DLBCL) is the most common

127 Diffuse large B-cell lymphoma (DLBCL) is the most common

128 Patients with relapsed diffuse large B-cell lymphoma (DLBCL) not eligible for a

129 A hallmark of the diffuse large B-cell lymphoma (DLBCL) of the activated B

130 Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma (DLBCL) of the elderly, in

131 Primary diffuse large B-cell lymphoma (DLBCL) of the ocular regi

132 utility of routine surveillance imaging for diffuse large B-cell lymphoma (DLBCL) patients achieving

133 nd thus its effect on response to therapy in diffuse large B-cell lymphoma (DLBCL) patients.

134 complete genome sequence analysis of primary diffuse large B-cell lymphoma (DLBCL) primary tumors and

135 phoma patients, transformation to aggressive diffuse large B-cell lymphoma (DLBCL) reduces median sur

136 The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) relies on chronic

137 apy plus consolidative radiotherapy (RT) for diffuse large B-cell lymphoma (DLBCL) remains controvers

138 apy (RT) after chemotherapy in limited-stage diffuse large B-cell lymphoma (DLBCL) remains controvers

139 he introduction of rituximab, survival after diffuse large B-cell lymphoma (DLBCL) remains heterogene

140 l-like (ABC) and germinal center B-cell-like diffuse large B-cell lymphoma (DLBCL) represent the 2 ma

141 Diffuse large B-cell lymphoma (DLBCL) represents a heter

142 Risk-stratification of diffuse large B-cell lymphoma (DLBCL) requires identific

143 uishes the aggressive activated B cell (ABC) diffuse large B-cell lymphoma (DLBCL) subtype from the b

144 The clinical features of diffuse large B-cell lymphoma (DLBCL) subtype of ocular

145 tinal B-cell lymphoma (PMBL) is a subtype of diffuse large B-cell lymphoma (DLBCL) that is putatively

146 ant to human NHL, we also analyzed 148 human diffuse large B-cell lymphoma (DLBCL) tumors and identif

147 The majority of diffuse large B-cell lymphoma (DLBCL) tumors contain mut

148 Patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) underwent both FLT

149 PET) biopsies from 344 patients with de novo diffuse large B-cell lymphoma (DLBCL) uniformly treated

150 lity therapy for patients with limited-stage diffuse large B-cell lymphoma (DLBCL) was shown in the S

151 The treatment of patients with diffuse large B-cell lymphoma (DLBCL) with cardiac comor

152 Diffuse large B-cell lymphoma (DLBCL) with MYC rearrange

153 iR-28 reexpression in human Burkitt (BL) and diffuse large B-cell lymphoma (DLBCL) xenografts blocked

154 evaluated in neuroblastoma, medulloblastoma, diffuse large B-cell lymphoma (DLBCL), and EOC microarra

155 including Burkitt lymphoma, Hodgkin disease, diffuse large B-cell lymphoma (DLBCL), and posttransplan

156 cance of MYC and BCL2 genetic alterations in diffuse large B-cell lymphoma (DLBCL), apart from transl

157 e to improving the survival of patients with diffuse large B-cell lymphoma (DLBCL), especially those

158 sented by the histologic transformation to a diffuse large B-cell lymphoma (DLBCL), is associated wit

159 eligible if they had relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle-cell lymph

160 n the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL), NF-kappaB activit

161 relapsed follicular lymphoma (FL), relapsed diffuse large B-cell lymphoma (DLBCL), or refractory agg

162 In diffuse large B-cell lymphoma (DLBCL), the number of cir

163 pathway may be usurped by tumors, including diffuse large B-cell lymphoma (DLBCL), to evade immune s

164 Nine patients had diffuse large B-cell lymphoma (DLBCL), two had indolent

165 n-Hodgkin lymphoma (NHL) subtypes, including diffuse large B-cell lymphoma (DLBCL), variably express

166 box protein 1 (FOXP1) is a common feature of diffuse large B-cell lymphoma (DLBCL).

167 th non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL).

168 alignancies including activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL).

169 t Hodgkin lymphoma (NLPHL) to transform into diffuse large B-cell lymphoma (DLBCL).

170 try (IHC) is associated with poor outcome in diffuse large B-cell lymphoma (DLBCL).

171 mutations are recurrently detected in human diffuse large B-cell lymphoma (DLBCL).

172 ignificant single-agent activity in relapsed diffuse large B-cell lymphoma (DLBCL).

173 ll receptor (BCR) signaling in cell lines of diffuse large B-cell lymphoma (DLBCL).

174 ttle is known of the role of this pathway in diffuse large B-cell lymphoma (DLBCL).

175 n disease progression and DNA methylation in diffuse large B-cell lymphoma (DLBCL).

176 e active in both major molecular subtypes of diffuse large B-cell lymphoma (DLBCL).

177 results of SC and ASCT for TRIL with de novo diffuse large B-cell lymphoma (DLBCL).

178 ng mutations in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).

179 r the activated B-cell-like subtype (ABC) of diffuse large B-cell lymphoma (DLBCL).

180 ) into an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL).

181 (HRPFS-male) was determined in patients with diffuse large B-cell lymphoma (DLBCL).

182 non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL).

183 f the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).

184 tion in the treatment of mutant MYD88(L265P) diffuse large B-cell lymphoma (DLBCL).

185 R) in tumor specimens from 244 patients with diffuse large B-cell lymphoma (DLBCL).

186 h the same regimen in patients with relapsed diffuse large B-cell lymphoma (DLBCL).

187 rest biopsy in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL).

188 , are frequently over-expressed in high-risk diffuse large B-cell lymphoma (DLBCL).

189 Confirmation of the diagnosis of diffuse large B-cell lymphoma (DLBCL).

190 tuximab exposure on outcome in patients with diffuse large B-cell lymphoma (DLBCL).

191 (MYC) and B-cell lymphoma gene-2 (BCL2), in diffuse large B-cell lymphoma (DLBCL).

192 nt of tumors from diverse origins, including diffuse large B-cell lymphoma (DLBCL).

193 ly increases the inhibitor's cytotoxicity in diffuse large B-cell lymphoma (DLBCL).

194 randomized clinical trials of patients with diffuse large B-cell lymphoma (DLBCL).

195 etermination of prognosis after treatment of diffuse large B-cell lymphoma (DLBCL).

196 atment purposes is increasingly impelling in diffuse large B-cell lymphoma (DLBCL).

197 pathobiology of several neoplasms including diffuse large B-cell lymphoma (DLBCL).

198 rous distinct B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL).

199 ofiling has identified 2 major subclasses of diffuse large B-cell lymphoma (DLBCL).

200 protein Galpha13, in Burkitt's lymphoma and diffuse large B-cell lymphoma (DLBCL).

201 %), in follicular lymphoma (FL, 70%), and in diffuse large B-cell lymphoma (DLBCL, 74%).

202 viduals did not receive cancer treatment for diffuse large B-cell lymphoma (DLBCL; adjusted odds rati

203 ; n = 28), follicular lymphoma (FL; n = 29), diffuse large B-cell lymphoma (DLBCL; n = 34), DLBCL ari

204 ed the global microRNA (miRNA) expression in diffuse large B-cell lymphoma (DLBCL; n = 79), Burkitt l

205 es occurred in the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; n=9), and three oc

206 ution to the diagnosis of CNS lymphoma in 91 diffuse large B-cell lymphomas (DLBCL) and 22 Burkitt ly

207 MYC rearrangements occur in 5% to 10% of diffuse large B-cell lymphomas (DLBCL) and confer an inc

208 GC B cell (GCB)-type diffuse large B cell lymphomas (DLBCLs) are mostly addic

209 Diffuse large B cell lymphomas (DLBCLs) arise from proli

210 In samples from patients with diffuse large B cell lymphomas (DLBCLs), PELI1 expressio

211 ed in various DNA repair pathways, mainly in diffuse large B cell lymphomas (DLBCLs).

212 tify HGBL-DH and will reclassify a subset of diffuse large B-cell lymphomas (DLBCLs) and HGBLs with f

213 Diffuse large B-cell lymphomas (DLBCLs) contain 2 major

214 Aggressive double- and triple-hit (DH/TH) diffuse large B-cell lymphomas (DLBCLs) feature activati

215 we show that patients with PRDM11-deficient diffuse large B-cell lymphomas (DLBCLs) have poorer over

216 series of Epstein-Barr virus-positive (EBV+) diffuse large B-cell lymphomas (DLBCLs) in young patient

217 tonic B-cell receptor (BCR) signal-dependent diffuse large B-cell lymphomas (DLBCLs) inhibits cellula

218 Human diffuse large B-cell lymphomas (DLBCLs) often aberrantly

219 negative prognostic impact in patients with diffuse large B-cell lymphomas (DLBCLs) treated with imm

220 terminal hydrolase L1 (UCH-L1) is induced in diffuse large B-cell lymphomas (DLBCLs), and that levels

221 previously reported that early-stage gastric diffuse large B-cell lymphomas (DLBCLs), including DLBCL

222 In diffuse large B-cell lymphomas (DLBCLs), JAK signaling i

223 diagnostic and discovery tool in 78 primary diffuse large B-cell lymphomas (DLBCLs).

224 eat the HCV-positive patients suffering from diffuse large B-cell lymphomas (DLBCLs).

225 ients with follicular lymphoma (FL), 16 with diffuse large B-cell lymphoma (DLCL), and 17 with mantle

226 the study: eight with relapsed or refractory diffuse large B-cell lymphoma (due to progressive diseas

227 y rearranged in PMBCL (20%) as compared with diffuse large B-cell lymphoma, follicular lymphoma, and

228 day), and six additional patients (two with diffuse large B-cell lymphoma, four with indolent lympho

229 However, distinguishing vitreoretinal diffuse large B-cell lymphoma from uveitis remains diffi

230 Germinal centre B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL) is a common ma

231 ociated with the germinal center (GC) B-cell diffuse large B-cell lymphoma (GCB-DLBCL) subtype.

232 place of JAK2 inhibitors in the treatment of diffuse large B-cell lymphoma has not been defined; we s

233 Moreover, some human diffuse large B-cell lymphomas have inactivating mutatio

234 e lymphomas, which occur in <10% of cases of diffuse large B-cell lymphoma, have been referred to as

235 -cell lymphomas, including Burkitt lymphoma, diffuse large B-cell lymphoma, Hodgkin lymphoma, and pri

236 as limited prognostic value in patients with diffuse large B-cell lymphoma homogeneously treated with

237 tly mutated genes in follicular lymphoma and diffuse large B cell lymphoma; however, the biological c

238 s to predict survival time for patients with diffuse large B-cell lymphoma, illustrate the behavior o

239 ollicular lymphoma in Scotland and Wales and diffuse large B-cell lymphoma in eastern Europe).

240 y rate for all ages in all areas, except for diffuse large B-cell lymphoma in eastern Europe.

241 lity in patients with follicular lymphoma or diffuse large B-cell lymphoma in five large European are

242 The assignment of diffuse large B-cell lymphoma into cell-of-origin (COO)

243 Vitreoretinal diffuse large B-cell lymphoma is a rare disorder, occurr

244 aggressive activated B cell-like subtype of diffuse large B-cell lymphoma is characterized by aberra

245 The situation in diffuse large B-cell lymphoma is deceiving, as the possi

246 lthough survival for follicular lymphoma and diffuse large B-cell lymphoma is improving, the results

247 CT) as first-line treatment in patients with diffuse large B-cell lymphomas is still a matter of deba

248 Diffuse large-B-cell lymphoma is curable, but when treat

249 Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), oc

250 P is a frequent feature of primary cutaneous diffuse large B-cell lymphoma, leg-type (PCLBCL-LT), rep

251 ose-escalation phase (part 1), patients with diffuse large B-cell lymphoma, mantle-cell lymphoma, or

252 40% among patients with follicular lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and pe

253 node biopsy samples, including FL (n = 20), diffuse large B-cell lymphoma (n = 10), classical Hodgki

254 rate was 69% across NHL subtypes and 55% for diffuse large B-cell lymphoma (n = 11); median response

255 s were treated (follicular lymphoma, n = 10; diffuse large B-cell lymphoma, n = 11; other B-cell lymp

256 with Hodgkin's lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphomas, nasopharyngeal carcinoma

257 Eligible patients had diffuse large-B-cell lymphoma, no evidence of indolent l

258 patients with nongerminal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL) were rando

259 ciated with increased NHL risk, specifically diffuse large B-cell lymphoma (odds ratio (OR) = 3.11, 9

260 directed CAR (CTL019) to treat patients with diffuse large B-cell lymphoma or follicular lymphoma tha

261 Patients with diffuse large B-cell lymphoma or follicular lymphoma tha

262 CI), 1.35-8.71] and, based on small numbers, diffuse large B-cell lymphoma (OR, 5.31; 95% CI, 1.54-18

263 h consisted of patients with newly diagnosed diffuse large B-cell lymphoma (part 2).

264 Lymphoma cells from diffuse large B-cell lymphoma patients had high basal ph

265 Neither DS nor risk stratification of diffuse large B-cell lymphoma patients is affected by th

266 ted genetic variants that predict outcome in diffuse large B-cell lymphoma patients treated with immu

267 ditionally, ASO-based MDM4 targeting reduced diffuse large B cell lymphoma PDX growth.

268 1.29) and was significantly associated with diffuse large B cell lymphoma (pooled HR per SD: 1.47; 9

269 Here, we show that diffuse large B-cell lymphomas possess a self-organized

270 h bulky stage 2-3 or stage 3-4 CD20-positive diffuse large B-cell lymphoma, previously untreated, and

271 phase 2 trial, we enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cel

272 e for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL).

273 exposure was associated with a lower risk of diffuse large B-cell lymphoma (relative risk = 0.68, 95%

274 me for elderly patients with newly diagnosed diffuse large B-cell lymphoma remains suboptimal in the

275 ents with various NHL histologies, including diffuse large B-cell lymphoma, Richter's transformation,

276 ggressive lymphomas, the association between diffuse large B-cell lymphoma risk and slope was restric

277 gle-agent polatuzumab vedotin (14 of 25 with diffuse large B-cell lymphoma, seven of 15 with indolent

278 ed with the activated B cell-like subtype of diffuse large B cell lymphoma somehow perturb ID-mediate

279 y, oncogenic CARD11 variants associated with diffuse large B cell lymphoma spontaneously induce Lin(U

280 sisted of follicular lymphoma misgrading and diffuse large B-cell lymphoma subtype misclassification.

281 ed a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed high-grade B-cell

282 ion-based signatures have been identified in diffuse large B-cell lymphoma that are predictive for su

283 on, which is impaired in approximately 6% of diffuse large B-cell lymphomas that carry inactivating g

284 nal B-cell lymphoma is a distinct subtype of diffuse large-B-cell lymphoma that is closely related to

285 HOP-21 chemotherapy for previously untreated diffuse large B-cell lymphoma; therefore, R-CHOP-21 rema

286 -based signatures on 2 sets of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHO

287 .2 and 6q21 with EFS and OS in patients with diffuse large B-cell lymphoma treated with immunochemoth

288 Nineteen patients had diffuse large B-cell lymphoma, two patients had follicul

289 Current diagnostic tests for diffuse large B-cell lymphoma use the updated WHO criter

290 dgkin lymphoma and eight of 20 patients with diffuse large B-cell lymphoma vs one of 15 patients with

291 alignancies, including mantle cell lymphoma, diffuse large B-cell lymphoma, Waldenstroms macroglobuli

292 ing the risk of prostate cancer mortality or diffuse large B-cell lymphoma was limited.

293 Overall, 126 patients with diffuse large B-cell lymphoma were included (56 female a

294 Patients with any stage of diffuse large B-cell lymphoma were treated with six cycl

295 elapsed/refractory NHL, who included 14 with diffuse large B-cell lymphoma, were enrolled; 42 receive

296 ion and STAT3 DNA binding in two subtypes of diffuse large B-cell Lymphoma, were used for benchmarkin

297 on after chemoimmunotherapy in patients with diffuse large B-cell lymphoma who are not candidates for

298 llow-up of 28.6 months, 86% of patients with diffuse large B-cell lymphoma who had a response (95% CI

299 All 18 patients with diffuse large B-cell lymphoma who received the recommend

300 to 50% of patients with Hodgkin lymphoma and diffuse large B-cell lymphoma will relapse, requiring ad